- Home
- BME vs ALT Comparison
BME vs ALT Comparison
Compare BME & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BME
- ALT
- Stock Information
- Founded
- BME 2005
- ALT 1997
- Country
- BME United States
- ALT United States
- Employees
- BME N/A
- ALT N/A
- Industry
- BME Trusts Except Educational Religious and Charitable
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- BME Finance
- ALT Health Care
- Exchange
- BME Nasdaq
- ALT Nasdaq
- Market Cap
- BME 525.3M
- ALT 472.3M
- IPO Year
- BME N/A
- ALT N/A
- Fundamental
- Price
- BME $40.21
- ALT $6.43
- Analyst Decision
- BME
- ALT Strong Buy
- Analyst Count
- BME 0
- ALT 7
- Target Price
- BME N/A
- ALT $20.83
- AVG Volume (30 Days)
- BME 34.0K
- ALT 2.0M
- Earning Date
- BME 01-01-0001
- ALT 02-27-2025
- Dividend Yield
- BME 6.26%
- ALT N/A
- EPS Growth
- BME N/A
- ALT N/A
- EPS
- BME 1.44
- ALT N/A
- Revenue
- BME N/A
- ALT $52,000.00
- Revenue This Year
- BME N/A
- ALT N/A
- Revenue Next Year
- BME N/A
- ALT N/A
- P/E Ratio
- BME $28.37
- ALT N/A
- Revenue Growth
- BME N/A
- ALT N/A
- 52 Week Low
- BME $35.53
- ALT $5.28
- 52 Week High
- BME $43.20
- ALT $14.84
- Technical
- Relative Strength Index (RSI)
- BME 50.67
- ALT 42.82
- Support Level
- BME $40.01
- ALT $6.06
- Resistance Level
- BME $40.55
- ALT $7.10
- Average True Range (ATR)
- BME 0.38
- ALT 0.36
- MACD
- BME -0.11
- ALT 0.03
- Stochastic Oscillator
- BME 17.09
- ALT 33.33
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.